Hikma Pharmaceuticals Plc · LSE:HIK
Hikma Pharmaceuticals — Investor Presentation (March 2021)
26 slides from Hikma Pharmaceuticals's investor presentation, March 2021
Slide 1: Meet the Management Series - Injectables
Better health. Within reach. Every day. Meet the Management Series - Injectables March 2021
Slide 2: Disclaimer
Disclaimer Save to the extent required by law, neither Hikma Pharmaceuticals PLC nor any of its affiliates (Hikma), nor any other party, is under any duty to update or inform you of any changes to such information. In particular, it should be noted that the financial information relating to Hikma co
Slide 3: Agenda and speakers
Agenda and speakers 2:05 –2:10pm Welcome Siggi Olafsson 2:10 –2:20pm Injectables overview Riad Mishlawi Siggi Olafsson Riad Mishlawi CEO President of 2:20 –2:30pm Operations Frank Savastano Injectables 2:30 –2:40pm US commercial Joel Rosenstack 2:40 –2:45pm Wrap up Riad Mishlawi Frank Savastano Joel
Slide 4: Injectables - Our largest business segment
Injectables - Our largest business segment Injectables Generics Branded 2020 revenue 42% 32% 26% 2020 core operating profit contribution1 57% 24% 19% 1 Core operating profit is $566 million. Before unallocated corporate costs of $98 million and operating profit from Other business of zero, core oper
Slide 5: Global Injectables
Global Injectables Riad Mishlawi, President of Injectables
Slide 6: Successful expansion driven by organic growth and M&A
Successful expansion driven by organic growth and M&A (million) Core revenue Cherry Hill Portugal Core operating profit Acquired • Pre-filled syringes • High-containment facility Bedford Labs Portugal $1,000 • >100 ANDAs Cherry Hill • Lyophilization expansion Acquired • Significant expansion • Expan
Slide 7: Our Injectables business today
Our Injectables business today Revenue grew at CAGR of 20% since acquisition of Baxter’s MSI Injectables in 2010 Top 3 generic Injectables manufacturer in the US 2020 revenue 42% 5 manufacturing sites around the world 3 core geographies 2020 core operating profit contribution1 57% 1 billion units of
Slide 8: A top supplier in the competitive US market
A top supplier in the competitive US market US generic injectables market share by volume1 US generic injectables market share by sales1 Pfizer Sanofi Fresenius Pfizer has 4 products Viatris’ in its portfolio top 2 products Top three with the largest make up 60% Viatris manufacturers making up 97% >
Slide 9: Higher-value products driving growth in MENA
Higher-value products driving growth in MENA MENA markets Jordan Sudan KSA 2020 revenue by country Iraq Morocco Other Egypt Algeria Lebanon MENA highlights Strategic priorities • Broad portfolio of 110 products • Strengthening local presence • Significant sales force - launching new products across
Slide 10: A strong foothold in Europe and expanding portfolio into new markets
A strong foothold in Europe and expanding portfolio into new markets Hikma’s Europe Injectables revenue ($million) Europe highlights 155 Germany • Broad product portfolio of 88 products 39% • Strong local manufacturing in Portugal, Italy Germany and Italy supporting increased contract manufacturing
Slide 11: Our strategic priorities for delivering sustainable growth
Our strategic priorities for delivering sustainable growth Grow portfolio in the Develop more Add capabilities and Expand geographic Identify and pursue US and diversify complex products new technologies and reach adjacent business customer base and increase number fill pipeline gaps opportunities o
Slide 12: Operations
Operations Frank Savastano, SVP & General Manager
Slide 13: Our extensive manufacturing capabilities and geographic footprint
Our extensive manufacturing capabilities and geographic footprint Germany US Portugal Italy Algeria New injectables facility under construction Egypt US Portugal Italy Germany Egypt Prefilled syringe IV bags Drug delivery Lyophilised systems Large parenteral Small parenteral Cytotoxic/high containme
Slide 14: Diverse manufacturing capabilities support our broad portfolio
Diverse manufacturing capabilities support our broad portfolio Our differentiated capabilities & state of the art technology... Drug delivery systems • Prefilled syringes • Sterile bags • Lyophilised products • Powder filling • Ampoules • Vials Specialised products • Antibiotics and hormones • Contr
Slide 15: Continued investment in capacity and capabilities underpins our strategy
Continued investment in capacity and capabilities underpins our strategy Our differentiated ...investing in capacity capabilities & state of and expanding our the art technology... capabilities... Near and long-term Drug delivery systems investments underway: • Prefilled syringes • Increased capacit
Slide 16: Our quality track record differentiates us from our peers
Our quality track record differentiates us from our peers Our differentiated ... investing in capacity ...our focus on quality, capabilities & state of and expanding our efficiency the art technology... capabilities... and flexibility... Near and long-term Drug delivery systems • Successful EMA and
Slide 17: A partner of choice for customers across our markets
A partner of choice for customers across our markets Our differentiated ... investing in capacity ...our focus on quality, Best in class capabilities & state of and expanding efficiency operations the art technology... our capabilities... and flexibility... Near and long-term Capabilities Drug deliv
Slide 18: US commercial
US commercial Joel Rosenstack, Chief Commercial Officer – US Injectables
Slide 19: Benefitting from a broad and diversified portfolio in the US
Benefitting from a broad and diversified portfolio in the US Ongoing expansion of our US Injectables core revenue US injectables portfolio from top 10 products 115 products across 14 therapeutic areas 115 108 97 89 2016 2020 72 contributed contributed 60% 42% 2016 2017 2018 2019 2020 Hikma Pharmaceu
Slide 20: Our evolving customer base
Our evolving customer base Key US injectable customer segments1 Evolving customer landscape Shortage Partnering with customers including Wholesalers and oncology Prevention Government Civica Rx, Vizient and Premier to distribution Agreements help reduce drug shortages Other2 Partnering with compound
Slide 21: Reducing shortages in the US market
Reducing shortages in the US market US Injectables shortage products1 >100 products in shortage are injectables Hikma is supplying c.50 short supply products 1 ASHP shortage list as at 17 March 2020 Hikma Pharmaceuticals PLC 21
Slide 22: Managing the impact of COVID-19
Managing the impact of COVID-19 Impact on elective surgeries in the US1 Demand for Hikma’s COVID-19 related products3 40% Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar 20% Diversified portfolio enabled us to respond to variability in demand for 0% injectable products – saw an increase in -20%
Slide 23: Outlook
Outlook Riad Mishlawi, President of Injectables
Slide 24: Building our differentiated pipeline through internal R&D and partnerships
Building our differentiated pipeline through internal R&D and partnerships Injectables pipeline of 164 molecules1 Adding complex products through partnerships Filed Top 20 business development products 80 products Require bioequivalence study Niche high-barrier 2 35 11 34 products 7 3 First to marke
Slide 25: Leveraging our strengths to deliver sustainable growth
Leveraging our strengths to deliver sustainable growth Our Strategy: Our priorities: Operations Diversification & Expansion • Maximise operational efficiency • Sustain high operating margins. • Identify and pursue adjacent Mid to high- • Add capacity, capabilities and new technologies business oppor
Slide 26: Meet the Management
Meet the Management Join us next for: Branded in June Generics in September Group in December Confidential
Hikma Pharmaceuticals — Investor Presentation (March 2021) on 6ix